Good morning. It’s Thursday and we’re diving into the explosive growth of wearable healthcare tech, why healthcare is falling behind in AI adoption, telemedicine’s shifting global power balance, and the record-breaking race to develop the next blockbuster obesity drug.

First time reading? Join healthcare execs and innovators who rely on Healthcare150 for sharp, data-driven insights. Subscribe here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

The Future of Wearable Healthcare Devices: A Market Poised for Exponential Growth

Healthcare is no longer confined to clinics, hospitals, or physician offices, it's increasingly worn on our wrists, wrapped around our arms, and embedded in our clothing. The wearable healthcare devices market is at the center of a technological and clinical revolution, poised to grow from $14.5 billion in 2020 to over $76 billion by 2029. This explosive trajectory reflects more than just consumer demand, it signals a fundamental shift in how healthcare is delivered, monitored, and monetized.

This report explores the unprecedented rise of wearable health tech, from the rapid acceleration in global shipments (expected to hit 440 million units by 2024) to the evolving role of smartwatches, medical sensors, and AI-powered diagnostics. With use cases expanding from fitness tracking to chronic disease management, eldercare, and mental health monitoring, investors are looking at a market ripe for disruption and growth. From category leaders like Omron and Fitbit to emerging pioneers in neurological and metabolic wearables, we break down the landscape, forecast the next wave of M&A and innovation, and pinpoint where capital should flow next. For institutional investors, tech leaders, and healthcare innovators, this is more than a trend, it’s the future of patient-centered care, made wearable.

Want to learn more?

Premium Perks

Since you are an Executive Subscriber, you get access to all the full length reports our research team makes every week. Interested in learning all the hard data behind the article? If so, this report is just for you.

Want to check the other reports? Access the Report Repository here.

Pharma’s Next Jackpot: Obesity Drug Trials Hit Record Highs

The weight-loss drug wars are in full swing, and the data proves it: 2024 set a record for obesity clinical trials, and 2025 is on track to shatter it. The number of innovator drug trials has surged past 70%, fueled by the runaway success of GLP-1R drugs like Wegovy and Zepbound.

With $125B in projected sales by 2033, pharma giants and biotech disruptors alike are racing to loosen Novo Nordisk and Eli Lilly’s grip on the market. Tech is playing its part too—13% of 2024’s trials leveraged virtual tools like wearables and sensors to improve patient engagement.

The bottom line? Obesity isn’t just a health crisis anymore—it’s a massive business opportunity. Learn More about the Obesity Drugs Market.

In Partnership with Build Wealth

Walker Deibel’s Latest Investment Opportunity Is Now Live!  Over 40% Subscribed In the First 48 Hours

Deal #5 is officially open to accredited investors. $5 million has already been subscribed in just 11 days, with an additional $2.5 million just released for allocation!

Why is Walker Deibel personally participating? The serial entrepreneur, WSJ bestselling author, and founder of Build Wealth sees this fund as hitting all facets of his Growth Predictor Framework:

• Experienced Operating Team – A track record of strong outcomes, including IRRs up to 81%

• Attractive Returns – Walker’s current position yields 14% annually, with a projected 35% IRR

• Institutional-Level Terms – Direct access to a $5M buy-in structure, reflecting an estimated 7% paper gain

• Focused Sector Approach – A strategic roll-up in an underserved industry with rising demand

Walker is co-investing his own capital in this opportunity. If you’re an accredited investor, you can review the overview and request your allocation.

👉 Discover the deal

For questions, reach out to Mike Brown, Head of Investor Relations: [email protected]

AI Can’t Save Healthcare from the Sidelines

While 83% of executives see AI boosting employee efficiency and 77% link it to revenue growth, too many initiatives remain stuck in small-scale trials.

🔹 Scaling AI is key: Piecemeal adoption is keeping healthcare behind retail and finance, which have already integrated AI into workflows for cost savings and better customer engagement.
🔹 C-Suite alignment is lacking: Only half of IT execs say AI strategies align with business goals, stalling enterprise-wide adoption.
🔹 Proven impact: AI-powered call centers can increase worker capacity by 30%, cutting patient wait times and improving service—yet only 3% of healthcare leaders prioritize this use case.

With $10.3T in potential economic value at stake, healthcare can’t afford to sit back. The winners will be those who scale AI now—not later.

A Biotech Marriage with $621M Vows

Patricia Industries is going all-in on analytical instruments, merging Advanced Instruments (its portfolio company) with Nova Biomedical in a deal that combines two niche leaders into a $621M sales-generating platform. The combined entity will keep the Nova Biomedical name and focus on biopharma and clinical tools. Byron Selman of Advanced will run the show, while Nova’s founders transition to consulting roles. The marriage, still pending regulatory approval, is expected to close in Q3 2025.

UBS and Simpson Thacher advised Advanced, while Jefferies and Davis Polk backed Nova. Over the last decade, the two have averaged 8% organic growth, proving that even in a slow-burn sector, compounding still works. Bottom line: this is a platform bet with R&D firepower and legacy founder credibility.

Love Healthcare150? Receive the Same Weekly Newsletter For the Private Equity Market!

PE150 delivers proprietary insights, market trends, and actionable tools for Private Equity & M&A professionals—in just one 5 minute weekly email. Subscribe now

Regional Focus: Telemedicine’s Global Power Shift

Telemedicine’s footprint is growing worldwide, but North America (34%) and Europe (29%) still dominate the market. However, APAC (26%) is closing the gap fast, fueled by rising healthcare demand and digital adoption.

Why it matters: While developed markets lead in telehealth infrastructure, emerging regions are the next frontier. Latin America (8%) and MEA (3%) remain underpenetrated, but as regulatory frameworks and internet access improve, expect investment to follow.

The real question: Will APAC surpass Europe as the second-largest telemedicine market, and how soon?

"The road to success and the road to failure are almost exactly the same"

Colin R. Davis